FindMyKOL

Olwen Hahn, MD

Basic profile

Alliance for Clinical Trials in Oncology

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionChicago, IL · MidwestSpecialtyHematology / OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding2022–2025Why? →

Olwen Hahn is an Oncology physician affiliated with Alliance for Clinical Trials in Oncology. OpenAlex indexes 119 publications with 5,443 citations (h-index 32).

Overview

Scholarship

indexed output and impact (OpenAlex)
119publications

Publications indexed by OpenAlex. Counts exclude supporting files.

5,443citations

Citations across these publications.

32h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
3companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2022–2025

Federally funded research awards.

View funding ↓

Industry payments

3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Pfizer
    Program year202530 paymentsResearch
    $11,339,771
  • AstraZeneca
    Program year20251 paymentResearch
    $39,174
  • Genentech
    Program year20257 paymentsResearch
    $15,602
All 21 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    97%
    Aromatase Inhibitor62.8%
    Anastrozole68%Letrozole17%Exemestane15%
    Part D≥50 patients
    Kinase inhibitor18.2%
    Verzenio42%Kisqali33%Ibrance24%
    Part D<11 patients

    + 3 more classes in this area

  • Blood & clotting

    3%
    Factor Xa inhibitor3%
    Xarelto100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 2022–2025 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”